A health plan's integration of molecular diagnostics and the impact on treatment pathways for quality care.

This Mid-Atlantic area Blues plan views genetic biomarkers as an important advancement in predicting recurrence rates and response to chemotherapy in estrogen-receptor-positive, node-negative, HER2-negative women with early-stage breast cancer. Care-First's Pay for Quality oncology program strives to combine clinically sound treatment with stable outcomes and predictable costs.